Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 10,000 Shares of Stock

Key Points

  • CEO Bobak Azamian sold 10,000 shares for $803,100 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 1.21%; he retained 817,991 shares.
  • Tarsus reported quarterly revenue of $194.57 million, above expectations, but EPS of -$14.40 substantially missed the consensus estimate of -$1.46.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $104.57; price targets cited ranged from $97 to $110.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,000 shares of the company's stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $80.31, for a total transaction of $803,100.00. Following the completion of the sale, the chief executive officer owned 817,991 shares in the company, valued at approximately $65,692,857.21. This trade represents a 1.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $78.20 on Wednesday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $53.89 and a fifty-two week high of $91.53. The company has a 50 day simple moving average of $74.42 and a two-hundred day simple moving average of $68.11. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of -5.15 and a beta of 0.34. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.94 and a current ratio of 1.96.




Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. The business had revenue of $194.57 million for the quarter, compared to analysts' expectations of $187.83 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -15.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC boosted its stake in Tarsus Pharmaceuticals by 295.0% during the 2nd quarter. Hsbc Holdings PLC now owns 38,090 shares of the company's stock valued at $2,429,000 after purchasing an additional 28,447 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $7,204,000. Bank of America Corp DE increased its holdings in shares of Tarsus Pharmaceuticals by 57.5% in the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company's stock worth $83,786,000 after purchasing an additional 436,271 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $23,249,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $5,726,000. 90.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TARS shares. HC Wainwright raised their price objective on Tarsus Pharmaceuticals from $88.00 to $106.00 and gave the company a "buy" rating in a research report on Wednesday, November 4th. Barclays began coverage on Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They set an "overweight" rating and a $110.00 price objective for the company. Zacks Research raised Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. Finally, Guggenheim raised their price target on Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the company a "buy" rating in a report on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $104.57.

Check Out Our Latest Stock Analysis on Tarsus Pharmaceuticals

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company's work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions. Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.

Featured Articles

Insider Buying and Selling by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Tarsus Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Tarsus Pharmaceuticals and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles